menu
    • menu
    [{"orgOrder":0,"company":"EpiPharm","sponsor":"CalciMedica","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"CM5480","moa":"CARC channel","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"EpiPharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"EpiPharm \/ CalciMedica","highestDevelopmentStatusID":"4","companyTruncated":"EpiPharm \/ CalciMedica"},{"orgOrder":0,"company":"EpiPharm","sponsor":"CycloLab Cyclodextrin Research and Development Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Conjugated cyclodextrin-peptide therapies","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"EpiPharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"EpiPharm \/ Cyclolab","highestDevelopmentStatusID":"4","companyTruncated":"EpiPharm \/ Cyclolab"}]

    Find Clinical Drug Pipeline Developments & Deals by EpiPharm

    Menu

    EpiPharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EpiPharm

                            Switzerland arrow
                            Duphat
                            Not Confirmed

                            EpiPharm

                            Switzerland arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Conjugated cyclodextrin-peptide therapies

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : CycloLab Cyclodextrin Research and Development Laboratory

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cyclolab and EpiPharma Form Joint Venture Company Targetrin Therapeutics to Develop Conjugated Cyclodextrin Pe...

                            Details : Cyclolab and EpiPharma have signed an agreement to form a joint venture specialty pharmaceutical company to develop and commercialize novel conjugated Cyclodextrin – Peptide drug candidates for the treatment of debilitating CNS and Pulmonary diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            January 11, 2021

                            Lead Product(s) : Conjugated cyclodextrin-peptide therapies

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : CycloLab Cyclodextrin Research and Development Laboratory

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EpiPharm

                            Switzerland arrow
                            Duphat
                            Not Confirmed

                            EpiPharm

                            Switzerland arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CM5480

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Sponsor : CalciMedica

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CalciMedica Enters Research Pact with EpiPharma to Discover and Develop CRAC Channel Inhibitor Therapies

                            Details : CalciMedica to use EpiPharma’s state-of-the-art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate the discovery and development of CalciMedica’s CRAC channel inhibitor novel drug pipeline.

                            Brand Name : CM5480

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 21, 2020

                            Lead Product(s) : CM5480

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Sponsor : CalciMedica

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth